Immunotech Biopharm seeks nod for HK IPO
![Allergen_Pills_Pharma_23May2017_Fotolia_230x150](https://assets.euromoneydigital.com/dims4/default/ff1f869/2147483647/strip/true/crop/230x150+0+0/resize/840x548!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2F4f%2Fb7%2Faad4dc61b5e514a6a235499d7b5a%2Fallergen-23may2017-fotolia-230x150.jpg)
China’s Immunotech Biopharm has applied for listing approval in Hong Kong, aiming to raise more than $100m from its IPO, according to a source familiar with the matter.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: